MOMENTUM EL (Extended Longevity ICD)

TM

Models D120 and D121

• H
 eartLogic™ Heart Failure Diagnostic for detecting indications of worsening
heart failure status.
• E
 nduraLife™ Battery Technology provides more power to use more of the device, featuring projected
longevity up to 17.5 years for VR devices and 16.0 years for DR devices.*

* Assumes: 2.0V RA, 2.0V RV, 0% pacing, 700Ω, No LATITUDE, No Respiratory Rate Sensor, No Heart Failure Sensor Suite.

Mechanical Specifications
Size (cm)
Model Type Mass (g) Volume (cc) Connector Type (RA RV LV) C-Codes
(W x H x D)
D120 VR 5.37 x 7.79 x 0.99 70.7 31.5 RV: IS-1/DF-1 C1722
D121 DR 5.37 x 7.79 x 0.99 71.0 31.5 RA: IS-1; RV: IS-1/DF-1 C1721

Pulse Generator Life Expectancy Estimation (Implant to Explant) with EnduraLife Battery (All Models)
EnduraLife Battery Technology provides clinically proven, industry-leading projected longevity1-10. The following tables represent sample pulse generator
life expectancy estimation (implant to explant) with EnduraLife battery as provided in product labeling. For specific programmable parameter ranges,
refer to product labeling at www.bostonscientific.com/manuals, or contact Boston Scientific technical services or your local representative.

700Ω
Pacing 500Ω 700Ω 900Ω
Projected Longevitya Type
Amplitude
Pacing
with LATITUDE™b with LATITUDE™b with LATITUDE™b
no LATITUDE™c
RS, or HFSS
VR
Typical programmed setting VR 2.5 V 15% 15.0 15.1 15.2 17.1
Maximum labeled longevity VR 2.0 V / Off 0% 15.4 15.4 15.4 17.5
DR
Typical programmed setting DR 2.5 V 15% 13.6 13.7 13.8 15.4
Maximum labeled longevity DR 2.0 V 0% 14.2 14.2 14.2 16.0

•A  ssumes 70 PPM LRL; DDDR mode; 0.4 ms Pulse Width (RA, RV); sensors On, Heart Failure Sensor Suite On.
•P  rojected longevity is calculated assuming 2 maximum energy charging cycles per year, including automatic capacitor re-forms and therapeutic
shocks. These calculations also assume 3-channel EGM Onset is on and that the pulse generator spends 3 months in Storage mode during
shipping and storage.
a. Assumes ZIP telemetry use for 2 hours at implant and for 40 minutes annually for in-clinic follow-up checks.
b. A
 ssumes standard use of the LATITUDE™ Communicator as follows: Daily Device Check on, quarterly scheduled remote follow ups,
and other typical interrogations.
c. Assumes LATITUDE™ Communicator is not used, Respiratory Sensor is Off, and Heart Failure Sensor Suite is Off.

Additional Longevity Information

• B oston Scientific devices have corporate warranties at 10 years (VR) and 8 years (DR) in available geographies.
Warranty information available at www.bostonscientific.com/warranty.
• Devices use Li/MnO2 chemistry.
• The Usable Battery Capacity is 1.9 Amp-hours (typical implant to battery capacity depleted).
• Shelf life is 2 years (before use by date).
MOMENTUM EL (Extended Longevity ICD)
TM

Models D432 and D433

Pacing Therapy Implant/In Clinic Follow-Up

Brady Modes Normal: DDD(R), DDI(R), VDD(R), VVI(R), AAI(R), Off Implant Programmable values: Enable use of ZIP™ telemetry (MICS)
Temporary: DDD, DDI, DOO, VDD, VVI, VOO, AAI, AOO, Off Communi­cation Mode (Requires initial use of wand for device ID) or use wand for
AT/AF Management ATR Mode Switch, Ventricular Rate Regulation (VRR) - all telemetry
MIN, MED, MAX, Atrial Flutter Response (AFR), PMT Nominal: Enable use of ZIP telemetry (Requires initial use of
Termination, Rate Smoothing wand for device ID)
Automaticity PaceSafe Right Ventricular Automatic Threshold (RVAT), In Clinic Follow-Up Wireless ECG
PaceSafe Right Atrium Automatic Threshold (RAAT)
Rate Adaptive Pacing Accelerometer with sensor trending function
RV Pacing Reduction AV Search+, RYTHMIQ™, AV Delays to 400 ms, Rate
Hysteresis Remote Follow-Up
Patient Triggered Triggers the storage of two minutes onset and one minute
Monitor (PTM) post – EGMs, intervals, and annotated marker data during a
symptomatic episode – by placing a magnet over the device
Patient Diagnostics Beeper Feature Beep during capacitor charge, beep when explant is
(Patient Alerts) indicated, beep when lead impedance measurement (shock
Daily Trends for Last Events, Lead impedances and amplitudes, RA Pace
or pace) is out-of-range
365 Days Threshold, RV Pace Threshold
Magnet Feature Magnet Response (Off, Store EGM, Inhibit Therapy)
Arrhythmia Logbook Events Summary, Stored Electrograms with Annotated
Remote Monitoring This device is designed to be LATITUDE™ enabled;
Markers, (Intervals and approximately 17 minutes of multi-
LATITUDE™ availability varies by region
channel EGM, always with 10 seconds Onset and event
storage prioritization). Implant activation of all available Thresholds Automatic storage of last successful daily PaceSafe
EGMs. On screen measurement of all stored signal threshold test for all active chambers
amplitudes and timing Wireless Remote follow-up for all devices (MICS)
Histograms & Tachy Events and Brady Counters
Counters
AT/AF Diagnostics Atrial Arrhythmia Report, AT/AF Burden, RV Rate During AT/
AF, Percent Pacing Tachyarrhythmia Therapy
Heart Failure Trends Heart Failure Management Report, Weight, Blood Pressure, Sensing/Detection Zones VF only, or VF and VT or VF, VT, VT-1
and Diagnostics Events, Activity Level, Respiratory Rate, Heart Rate, Heart Lowest Zone can be Monitor Only
Rate Variability (SDANN), HRV Footprint, Thoracic Impedance, Shock Reduction and AcuShock™ Advanced Technology including Onset/Stability™,
Night Heart Rate, Sleep Incline Appropriate Therapy RhythmID™ with RhythmMatch™, Dynamic Noise Algorithm
To note: Weight and Blood Pressure are only available via LATITUDE™ (DNA) for sensing, Automatic Gain Control (AGC) with
programmable sensing floor, Narrow Band Pass Filter
Antitachycardia Quick Convert™ in VF Zone. Two programmable ATP
Pacing Therapy (ATP) schemes in both VT and VT-1 zones. Burst, Ramp, Scan,
HeartLogicTM Heart Failure Diagnostic Termination Ramp-Scan
HeartLogicTM Heart The HeartLogic Index and Alert are a validated diagnostic Shock Energy 41 J stored, 35 J delivered. First two shocks in each zone
Failure Diagnostic tool to detect gradual worsening of heart failure over days programmable. VT-1 has 5 shocks. VT has 6 shocks and
or weeks using multiple physiological measurements. The VF has 8 shocks. Reverse Last Shock Polarity in zone.
HeartLogic Index aggregates measurements from multiple Programmable RV Coil to RA Coil and Can (TRIAD),
device-based sensors (Heart Sounds, Thoracic Impedance, RV Coil to Can, RV Coil to RA Coil (COLD CAN)
Respiration, and Night Heart Rate) and reflects changes Nominals VF Zone (200 bpm) – Detection: Rate and Duration, Therapy:
over time in the patient’s sensor trend data from their Quick Convert, 8 high energy shocks
respective baseline values. VT Zone (160 bpm) – Detection: Rhythm ID or
HeartLogicTM HeartLogicTM composite index and alert, S3 Heart Sound, Onset/Stability, Therapy: ATP x 2, 6 high energy shocks
Heart Failure S1 Heart Sound, Thoracic Impedance, Respiratory Rate,
Management Report Night Heart Rate, Sleep Incline, Activity Level, AT/AF Bur-
den, V therapy, RV Rate During AT/AF, Mean Heart Rate,
% LV Paced, Heart Rate Variability (SDANN), Weight,
Blood Pressure
To note: HeartLogicTM composite index and alert, heart sounds, weight,
and blood pressure are only available through LATITUDE.

Device Testing/Induction Methods

Induction Methods Vfib Induction, Shock on T Induction, Programmed Electrical
Stimulation (PES), 50 Hz/Manual Burst Pacing
Commanded Therapy Commanded Shock, Commanded ATP
Methods
 References:
1. Nine independent studies confirm that CRT-Ds powered by EnduraLife Battery Technology offer industry-leading longevity.

2. Haarbo J, Hjortshoj S, Johansen J, Jorgensen O, Nielsen J, Petersen H. Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs
Between Manufacturers: Data from the Danish ICD Registry. Presented at HRS 2014. http://ondemand.hrsonline.org/common/presentation-detail.aspx/15/35/1241/9000. Boston
Scientific = 136 patients, Medtronic = 651 patients, St. Jude Medical = 1,587 patients, Bitronik = 369 patients. Time to exchange of the device because of battery depletion or
device failure recorded in the Danish ICD Registry was the endpoint. The four-year survival rate for devices in the Danish Registry study was 81.1% for Medtronic and 95.7%
for Boston Scientific (P<0.01).

3. J. Williams, R. Stevenson. Contemporary cardiac resynchronization implantable cardioverter defibrillator battery longegity in a community hospital heart failure cohort.
Presented at HFSA 2014. http://www.onlinejcf.com/article/. S1071-9164 (14)00389-3/fulltext. Boston Scientific = 53 patients, Medtronic = 28 patients, St. Jude Medical
= 10 patients. Four-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

4. Ellis CR, Dickerman DI, Orton JM, Hassan S, Good EG, Okabe T, Andruilli JA, Quan KJ, Greenspoon AJ. Ampere Hour as a Predictor of Cardiac Resynchronization Defibrillator
Pulse Generator Battery Longevity: A Multicenter Study. PACE 2016 doi: 10.1111/pace.12831 first published online 11-MAR-2016. The five major institutions performing the
study include, at Vanderbilt University, Henry Ford Hospital, University of Michigan, Thomas Jefferson University, Cooper Health System, North Ohio Heart Center. Boston
Scientific = 322 patients, Medtronic = 794 patients, St. Jude Medical = 186 patients. Five-year survival rate calculated using device replacements for battery depletion as
indicated by ERI.

5. Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D’onofrio A, Stabile G, Crostao M, Petracci B, Ceriotti C, Bontempi L, Morosato M, Ballari GP, Gasparini M. Longevity
of implant Cardioverter-defibrillators for cardiacresynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and
manufacturer. Europace2015; 17:1251-58.doi:10.1093/eurospace/euv109. First published online: May 14, 2015. Medtronic = 532 patients, Boston Scientific = 291 patients,
St. Jude Medical = 106 patients, Biotronik = 20 patients, Sorin = 69. Five-year survival rate of latest marketed devices (between 2006 and 2010) calculated using device
repleacements for battery depletion as indicated by ERI.

6. Zanon F, Martignani C, Ammendola E, Menardi E, NarducciML, De Filippo P, Santamaria M, Campana A, Stabile G, Potenza DR, Pastore G, lori M, La Rosa C, and Biffi M. Device
Longevity in a Contemporary Cohort of ICD/CRT-D Patients Undergoing Device Replacement. Doi:10.1111/jce.12990, First published online 20-APR-2016. Comparison of device
longevity by Kaplan-Meier curves of CRT-D systems extracted between March 2013 and May 2015. Medtronic = 195 patients, Boston Scientific = 157 patients, St. Jude = 72,
Biotronik = 9.

7. Provided by Dr. Ernest Lau on 04/29/15 in support of Lau E, Wilson C, Ashfield K, McNair W, McEneany D, Roberts M, Large Capacity LiMn02 Batteries Extended CRT-D
Longevity in Clinical Use Compared to Smaller Capacity LiSVO Batteries Over 6 Years. Presented at HRS 2015. Medtronic = 62 patients, Boston Scientific = 27 patients,
St. Jude = 66 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

8. Von Gunten S, Schaer BA, Yap SC, Szili-Torok T, Kühne M, Sticherling C, Osswald S, Theuns DA. Longevity of implantable cardioverter defibrillators: a comparison among
manufacturers and over time. Europace. 2015 Nov 25. Epub 2015 Nov 25. Total patients = 3436.

9. Alam MB, Munir MB, Rattan R, Adelstein E, Jain S, Saba S. Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and
discrepancies with published product performance reports. Europace 016;doi:10.1093/europace/euw044. First published online: 22-MAR-2016. Kaplan Meier curves depicting
survival of CRT devices free from battery depletion by device manufacturer. Battery Longevity in Cardiac Medtronic = 416 patients, Boston Scientific = 173 patients, St. Jude
Medical = 57 patients. Previously evaluated these patients at a four-year survival rate calculated using device replacements for battery depletion as indicated by ERI. 2014;
Europace (2014) 16,246-51.

10. Shabanna Din, Shabanna, Mcgee, Rao, Archana, Wright, Jay D. Longevity of implantable cardioverter defibrillators: The impact of device manufacturer and device type on
device longevity were assessed. Europace. 2015 Nov 25; Epub 2015 Nov 25. Total patients = 3436. Cardiostim Abstract 2016. Total patients = 1489.

ICD Systems – RESONATE™ HF, RESONATE™ EL, PERCIVA™ HF, PERCIVA™, VIGILANT™ EL, MOMENTUM™ EL
INDICATIONS AND USAGE Boston Scientific implantable cardioverter defibrillators (ICDs) are intended to provide ventricular antitachycardia pacing (ATP) and ventricular
defibrillation for automated treatment of life-threatening ventricular arrhythmias.
CONTRAINDICATIONS Use of these Boston Scientific pulse generators are contraindicated for the following: patients whose ventricular tachyarrhythmias may have
reversible cause, such as: digitalis intoxication, electrolyte imbalance, hypoxia, sepsis; or patients whose ventricular tachyarrhythmias have a transient cause, such as:
acute myocardial infarction (MI), electrocution, drowning; or patients who have a unipolar pacemaker.
WARNINGS Read this manual thoroughly before implantation to avoid damage to the pulse generator and/or lead. For single patient use only. Do not reuse, reprocess, or
resterilize. Always have external defibrillation equipment available during implant and electrophysiologic testing. Ensure that an external defibrillator and medical personnel
skilled in CPR are present during post-implant device testing should the patient require external rescue. Do not use this pulse generator with another pulse generator. Program
the pulse generator Tachy Mode(s) to Off during implant, explant, or postmortem procedures to avoid inadvertent high voltage shocks. Do not kink, twist, or braid the lead with
other leads as doing so could cause lead insulation abrasion damage or conductor damage. For leads that require the use of a Connector Tool, use caution handling the lead
terminal when the Connector Tool is not present on the lead. Do not directly contact the lead terminal with any surgical instruments or electrical connections such as PSA
(alligator) clips, ECG connections, forceps, hemostats, and clamps. Do not contact any other portion of the DF4–LLHH or DF4–LLHO lead terminal, other than the terminal pin,
even when the lead cap is in place. Do not use atrial tracking modes in patients with chronic refractory atrial tachyarrhythmias. Tracking of atrial arrhythmias could result in
ventricular tachyarrhythmias. Advise patients to seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical
device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator. RESONATE HF, RESONATE, PERCIVA HF, PERCIVA, and VIGILANT Rhythm Management
devices with a DF4 right ventricular lead connection are considered MR Conditional. For these devices, unless all of the MRI Conditions of Use are met, MRI scanning of the Boston Scientific Corporation
patient does not meet MR Conditional requirements for the implanted system, and significant harm to or death of the patient and/or damage to the implanted system may
result. For potential adverse events applicable when the Conditions of Use are met or not met, refer to the MRI Technical Guide. Do not subject a patient with an implanted pulse 4100 Hamline Avenue North
generator and/or lead to diathermy. If desired, ensure that Patient Triggered Monitor is enabled prior to sending the patient home. Once the Patient Triggered Monitor feature has St. Paul, MN 55112-5798 USA
been triggered by the magnet and an EGM has been stored, or after 60 days have elapsed from the day that Store EGM was enabled, the patient should not apply the magnet. Tel: 651.582.4000 Fax: 651.582.4166
PRECAUTIONS For specific information on precautions, refer to the following sections of the product labeling: clinical considerations, sterilization and storage, implantation, Medical Professionals:
device programming, environmental and medical therapy hazards, hospital and medical environments, home and occupational environments, follow-up testing, explant and
disposal, and supplemental precautionary information.
1.800.CARDIAC (227.3422)
Patients and Families:
POTENTIAL ADVERSE EVENTS Potential adverse events include, but are not limited to, the following: allergic/physical/physiologic reaction, death, erosion/migration,
fibrillation or other arrhythmias, lead or accessory breakage (fracture/insulation/lead tip), hematoma/seroma, inappropriate or inability to provide therapy (shocks /pacing/sensing), 1.866.484.3268
infection, procedure related, and component failure. Patients may develop psychological intolerance to a pulse generator system and may experience fear of shocking, fear of www.bostonscientific.com
device failure, or imagined shocking. In rare cases severe complications or device failures can occur.
Refer to the product labeling for specific indications, contraindications, warnings/precautions and adverse events. Rx only. (Rev B) © 2017 Boston Scientific Corporation
or its affiliates. All rights reserved.

All trademarks are the property of their respective owners. CRM-483605-AA SEP2017